Tandem Diabetes Care
TNDM
200 hedge funds and large institutions have $1.81B invested in Tandem Diabetes Care in 2018 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 74 increasing their positions, 57 reducing their positions, and 30 closing their positions.
53% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 30
45% more call options, than puts
Call options by funds: $56.2M | Put options by funds: $38.8M
30% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 57
10.98% more ownership
Funds ownership: 72.15% → 83.13% (+11%)
9% more funds holding
Funds holding: 184 → 200 (+16)
2% more capital invested
Capital invested by funds: $1.77B → $1.81B (+$42.2M)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$66M |
| 2 |
Renaissance Technologies
New York
|
+$35.9M |
| 3 |
CCI
Columbus Circle Investors
|
+$28.5M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$19.4M |
| 5 |
DCM
Daruma Capital Management
New York
|
+$17.6M |
Top Sellers
| 1 |
HCM
Hitchwood Capital Management
New York
|
-$24.4M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$21.1M |
| 3 |
BC
Broadfin Capital
New York
|
-$17.1M |
| 4 |
Two Sigma Investments
New York
|
-$13.6M |
| 5 |
Goldman Sachs
New York
|
-$9.9M |
TNDM Hedge Fund Activity: Q4 2018 in Review
200 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q4 2018, worth a combined $1.81B — up 2.4% from $1.77B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new TNDM positions and 30 closed out — a net gain of 16 holders — while 74 added to existing stakes and 57 trimmed.
The largest buyer was Vanguard Group, adding an estimated $66M. The largest seller was Hitchwood Capital Management, exiting entirely with an estimated $24.4M sold.
- 200 institutional investors held Tandem Diabetes Care (TNDM) as of Q4 2018, up from 184 in Q3 2018.
- Funds reported $1.81B of Tandem Diabetes Care stock for Q4 2018, up 2.4% quarter-over-quarter.
- 46 funds opened new Tandem Diabetes Care positions in Q4 2018 and 30 closed out, a net change of +16 holders.
- The largest Tandem Diabetes Care buyer in Q4 2018 was Vanguard Group, an estimated $66M added.
- The largest Tandem Diabetes Care seller in Q4 2018 was Hitchwood Capital Management, an estimated $24.4M sold.
Based on aggregated 13F filings for Q4 2018.